Date Posted
This hybrid NASEM MCD workshop will examine the state of the science for clinical use of multi-cancer detection (MCD) tests. The NCI Division of Cancer Prevention staff will present on Monday, October 28. View the MCD Public Agenda.
Session 1: Overview of Multicancer Detection Testing (1 hour, 45 minutes)
Keynote Presentation: How Much Do You Want to Know? The Peril and Promise of an MCD-Driven Future (9:00-9:20 a.m.)
W. Kimryn Rathmell, M.D., Ph.D., M.M.H.C., Director, National Cancer Institute (NCI)
Panel Discussion on How Multicancer Detection Testing Works (9:50-10:45 a.m.)
Panelist: Christos Patriotis, Ph.D., Program Officer, Division of Cancer Prevention (DCP), NCI
Clinical Trials for Evaluating the Mortality Benefits of MCD Testing (11:10-11:20 a.m.)
Hormuzd Katki, Ph.D., Senior Investigator, Division of Epidemiology and Genetics, NCI
Session 2: MCD Test Validation (1 hour, 30 minutes)
Panel Discussion on MCD Test Validation (10:40-11:35 a.m.)
Panelist: Philip Castle, Ph.D., M.P.H., Director, Division of Cancer Prevention (DCP), NCI
Session 3: Examples of MCD Tests in Development and Clinical Use (1 hour, 20 minutes)
Co-Moderator: Philip Castle, Ph.D., M.P.H., Director, DCP, NCI
Overview of MCD Tests in Development and Clinical Practice (1:30-1:45 p.m.)
Wendy Rubinstein, M.D., Ph.D., Senior Scientific Officer, DCP, NCI